产品销售和分销 - 公司市场和销售了Tyvaso DPI、nebulized Tyvaso、Remodulin、Orenitram、Unituxin和Adcirca等商品[114] - Tyvaso DPI于2022年5月获FDA批准用于治疗肺动脉高压和肺间质性肺病相关肺动脉高压[114] - 公司与Accredo Health Group、CVS Specialty和ASD Specialty Healthcare等公司签有分销协议[115] - Remodulin在美国和欧洲面临来自仿制药的竞争,销售收入有所下降[116,118] 专利诉讼 - 公司正在与Liquidia公司就Yutrepia产品的专利权问题进行诉讼[119,120] - 公司正在与Sandoz和RareGen就Remodulin输注装置的专利权问题进行诉讼[116] - 公司与Watson、Actavis和ANI就其仿制品的上市时间达成了和解协议[118] - 公司正在评估是否进一步上诉关于'793专利的PTAB裁决[119] - 公司正在等待最高法院对'793专利的裁决[120] - 公司正在就Liquidia获得最终FDA批准的法院裁决提出上诉[119] 临床试验 - 公司正在进行两项针对特发性肺纤维化(IPF)的Tyvaso吸入剂的III期临床试验TETON 1和TETON 2[131] - 公司正在进行一项针对进行性肺纤维化(PPF)的Tyvaso吸入剂的III期临床试验TETON PPF[131] - 公司正在进行一项针对肺动脉高压(PAH)的新一代口服选择性前列环素受体激动剂Ralinepag的III期临床试验ADVANCE OUTCOMES[132] - 公司已获得IPF适应症的孤儿药认定[131] 器官制造和再生医学 - 公司正在研发多项技术以增加可移植器官的供给和改善移植结果,包括异种移植、再生医学、3D生物打印等[135] - 公司正在开发和商业化治疗罕见和危及生命疾病的疗法,并将器官制造视为广泛疾病的补充解决方案[136] - 公司的猪源器官移植项目包括三种处于开发阶段的器官产品,分别为UHeart、UKidney和UThymoKidney[137] - 公司已成功完成了两例猪心脏移植手术和一例猪肾移植手术,并在无脑死亡器官供体模型中进行了UKidney、UHeart和UThymoKidney的前期试验[137][138] - 公司收购了Miromatrix公司和IVIVA公司,分别开发生物人工肝脏和肾脏产品[139][141] - 公司的肺部再生医学项目包括ULobe和ULung两种产品[139] - 公司的无人机器人技术可以实现零碳足迹的器官运输[143] 财务表现 - 公司预计未来收入增长将主要来自Tyvaso DPI、Orenitram等产品的销售增长,以及新产品和适应症的开发[145] - 公司计划在未来三年内投资5.75亿美元用于新设施建设,主要用于Tyvaso DPI生产[146] - 公司面临来自大型制药公司的激烈竞争,以及新产品上市对现有产品的潜在冲击[146] - 公司总收入在2024年6月30日结束的三个月和六个月期间分别增长了26%和26%[154] - Tyvaso DPI产品销售额在2024年6月30日结束的三个月和六个月期间分别增长了56%和56%[150] - Remodulin产品销售额在2024年6月30日结束的三个月和六个月期间分别增长了11%和11%[150] - Orenitram产品销售额在2024年6月30日结束的三个月和六个月期间分别增长了16%和16%[150] - Unituxin产品销售额在2024年6月30日结束的三个月和六个月期间分别增长了18%和18%[150] - 公司在美国市场的总收入占比约为95%[152][153] - 公司在2024年6月30日的三个月和六个月期间分别计提了1.119亿美元和2.19亿美元的销售返利和折扣等费用[158][162] - 公司在2024年6月30日的三个月和六个月期间分别有1.327亿美元和1.327亿美元的销售返利和折扣等费用余额[158][162] - 公司在2024年6月30日的三个月和六个月期间的销售成本分别为1.236亿美元和2.394亿美元[165] - 公司销售成本(不含股份支付)在2024年6月30日结束的三个月和六个月期间较2023年同期有所增加,主要是由于Tyvaso DPI特许权使用费增加[166] - 研发费用(不含股份支付)在2024年6月30日结束的三个月和六个月期间较2023年同期有所增加,主要是由于与药物递送设备的预付非退还性许可费用和器官制造项目相关支出增加[169] - 销售、一般及管理费用(不含股份支付)在2024年6月30日结束的三个月和六个月期间较2023年同期有所增加,主要是由于法律费用增加和人员费用增加[170] - 股份支付费用在2024年6月30日结束的三个月和六个月期间较2023年同期大幅增加,主要是由于STAP奖励计划费用增加[173][174] - 其他收益(费用)净额在2024年6月30日结束的六个月期间较2023年同期有所增加,主要是由于权益证券的未实现收益增加[177] - 公司2024年上半年的所得税费用为1.692亿美元,有效税率为22%[178] - 公司于2024年3月启动了加速股票回购计划,总金额为10亿美元,截至2024年6月已完成8成回购[179] - 公司2024年6月30日和2023年12月31日的现金及现金等价物和有价证券投资总额分别为43.02亿美元和49.04亿美元,同比下降12%[180] - 公司2024年上半年经营活动

Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Catalent (CTLT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, w ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Catalent (CTLT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to ...

Have you been paying attention to shares of United Therapeutics (UTHR) ? Shares have been on the move with the stock up 11.6% over the past month. The stock hit a new 52-week high of $330 in the previous session. United Therapeutics has gained 46.2% since the start of the year compared to the 7.5% move for the Zacks Medical sector and the -3.5% return for the Zacks Medical - Drugs industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed our ...

United Therapeutics (UTHR) announced full enrolment in the phase III TETON 2 study evaluating a nebulized version of Tyvaso (treprostinil) in patients with idiopathic pulmonary fibrosis (IPF), a scarring disease of the lungs. The TETON 2 study is now enrolled with a total of 597 patients. Top-line data from this study is expected in second-half 2025. The FDA has already approved Tyvaso as an inhalation solution (nebulized) and dry powder inhaler (DPI) for treating pulmonary arterial hypertension (PAH) and p ...

EnglishItalianoEspañolPortuguêsDeutschالعربيةFrançaisImportant DisclaimersThe content provided on the website includes general news and publications, our personal analysis and opinions, and contents provided by third parties, which are intended for educational and research purposes only. It does not constitute, and should not be read as, any recommendation or advice to take any action whatsoever, including to make any investment or buy any product. When making any financial decision, you should perform your ...